Holen Sie sich die Stockscreener-App
1.49
2.61%
-0.04
Schlusskurs vom Vortag:
$1.53
Offen:
$1.53
24-Stunden-Volumen:
2,722
Relative Volume:
0.03
Marktkapitalisierung:
$78.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.61M
KGV:
-11.88
EPS:
-0.1254
Netto-Cashflow:
$-3.10M
1W Leistung:
-8.02%
1M Leistung:
+0.00%
6M Leistung:
-12.87%
1J Leistung:
-32.27%
1-Tages-Spanne:
$1.49
$1.53
1-Wochen-Bereich:
$1.395
$1.62
52-Wochen-Spanne:
$1.3401
$3.20
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Compare OKYO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.49 | 80.29M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
522.22 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
999.14 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.10 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.35 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-08 | Eingeleitet | B. Riley Securities | Buy |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
111-patient eye pain trial planned by OKYO Pharma (NASDAQ: OKYO) - Stock Titan
OKYO Pharma (OKYO) to Showcase Advances at Ophthalmology Futures Forum and ESCRS iNovation Day Amid Phase 3 NEPTUNE Trial Progress - kalkinemedia.com
A late-stage trial is planned to test a one-dose treatment for corneal nerve pain - Stock Titan
OKYO Pharma (NASDAQ: OKYO) readies Phase 3 trial of eye-pain drug urcosimod - Stock Titan
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference - marketscreener.com
About 111 people are planned for an eye-pain trial after U.S. regulator feedback validated OKYO's path - Stock Titan
OKYO Pharma Ltd ADR (NASDAQ: OKYO) Share Price, OKYO Stock News, OKYO Share Price & Updates - kalkine.ca
Piper Sandler Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OKYO (OKYO) Session: Posts a 2.67% Gain to $1.54 in Latest Trading; Chart Watch: Price Remains Between $1.46 Support and $1.62 Resistance in the Latest ReadingVolatility Surface - vinanet.vn
OKYO (OKYO) Watch: Declines 0.33% to $1.51 on the Day; Key Range: the Supplied Trading Band Runs From $1.43 to $1.59 for the Current SessionCounter Trend Trade - vinanet.vn
OKYO Pharma (OKYO) Edges Up 1.33% to $1.52 as Support at $1.44 HoldsCalendar Spread Trade - vinanet.vn
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4% - MarketBeat
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma (NASDAQ: OKYO) updates 20-F to add clawback policy exhibit - stocktitan.net
OKYO Pharma (OKYO) director buys 5,000 shares in open market - Stock Titan
OKYO Pharma (OKYO) Slips 2.6% to $1.49, Testing Key Support at $1.42Death Cross - vinanet.vn
Price to sales forward of OKYO Pharma Limited – NASDAQ:OKYO - tradingview.com
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday - MarketBeat
Form 4 OKYO Pharma Ltd For: 29 July By Investing.com - Investing.com Canada
OKYO Pharma CSO buys shares - Proactive financial news
OKYO Pharma CSO purchases additional shares at $1.49 By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial - Stock Titan
OKYO Pharma scientist's holdings reach 20,030 shares after purchase - Stock Titan
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - GlobeNewswire
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO|OKYO Pharma Ltd|Price:1.530|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma Declines Slightly, Tests Support Near $1.39 as Biotech Sector Faces PressureAccumulation Line - vinanet.vn
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director ups stake with 5,000-share purchase - Stock Titan
OKYO Pharma Announces Purchase of Shares by Director - GlobeNewswire
OKYO Pharma CEO purchases 15,000 shares at $1.54 each - Investing.com
OKYO Pharma CEO purchases 15,000 shares at $1.54 each By Investing.com - Investing.com South Africa
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):